Pfizer sets up Asia’s first global drug development centre in Chennai


PTI, May 4, 2022, 5:29 PM IST

Chennai: US pharmaceutical company Pfizer has set up its global drug development center at the Indian Institute of Technology-Madras Research Park here, at an outlay of over Rs 150 crore.

The center, which employs 250 scientists and technicians, would develop innovative formulations, small molecules, and active pharmaceutical ingredients (APIs).

According to company, the centre would develop and support products in global markets and Pfizer’s manufacturing centres, worldwide.

The facility is among 12 centres established worldwide, and the first in Asia.

Pfizer India, country manager, S Sridhar said, ”The Pfizer’s drug development centre at the IIT M Research Park is a positive opportunity to establish truly one of the most advanced laboratories that it is setting up for research and development, in Chennai and opportunity to showcase the potential of R&D in the country.” ”The world-class scientific, technology and innovation driven Research Park campus provides an ideal setting for our work. We are hopeful that the proximity to IIT Madras and other technology Research Park start-ups will also improve academia and industry partnerships..,” he said in a statement.

The company has invested USD 20 million (Rs 150 plus crore) in the centre spread across 61,000 square foot at the IIT-M Research Park.

The Centre integrates two functions under the export-oriented undertaking of Pfizer — Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT & E) Centre of Excellence.

While the Pharmaceutical Sciences division has been set up for dedicated development of anti-infectives, oncolytics, sterile injectables, the Global Technology and Engineering Centre of Excellence would be on active pharmaceutical ingredients process and manufacturing technology to supply medicines to patients.

”We are pleased to welcome the Pfizer global drug development centre to IIT-Madras Research Park. We believe the proximity of Pfizer to IIT-M, student, scientists and other leading industry start-ups will foster great collaboration between industry and academia,” IIT-M Research Park, President, Ashok Jhunjhunwala said.

IIT-M Director professor V Kamakoti said, ”drug development is one of the most important activities wherein technology meets medicine.” ”Aligning the process with regulatory conditions using technology will not only quicken but enhance the quality of the process of drug development”.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Gold prices crash by Rs 3,350 after govt cuts custom duty on bullion

Greater Bengaluru Governance Bill tabled in Karnataka Assembly

Budget 2024-25: Customs duty exemption on key cancer drugs to reduce cost

Karnataka HC grants bail to 2 accused in M M Kalburgi murder case

SC rules out cancellation, re-test of controversy-ridden NEET-UG 2024

Major fire on merchant navy ship off Karnataka coast extinguished, says Coast Guard

‘Kursi Bachao Budget,’ Rahul Gandhi slams Modi govt

Related Articles More

Gold prices crash by Rs 3,350 after govt cuts custom duty on bullion

Budget 2024-25: Customs duty exemption on key cancer drugs to reduce cost

IAS officer’s wife ends life, claims innocence in cases registered in Tamil Nadu in letter

Odisha: Man sentenced to 10 years in jail for raping woman

SC rules out cancellation, re-test of controversy-ridden NEET-UG 2024

MUST WATCH

Brahma Kumaris

Tapta Mudra Dharana

Banana Farming

Aghnashini River

Dr. Rajkumar


Latest Additions

Cooperative Society Amendment Bill passed in Karnataka Assembly amid BJP’s walkout

Davanagere: Catholic priest killed in road accident

Karnataka neglected in Union Budget, says CM Siddaramaiah

Gold prices crash by Rs 3,350 after govt cuts custom duty on bullion

Greater Bengaluru Governance Bill tabled in Karnataka Assembly

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.